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ydniu@126.com (Abstract Farnesoid X receptor (FXR, also termed nuclear receptor NR1H4) is critically involved in the
regulation of nascent bile formation and bile acid enterohepatic circulation. FXR and bile acids have
been shown to play roles in liver regeneration and inﬂammatory responses. There is increasing evidence
suggesting that FXR and the FXR signaling pathway are involved in the pathophysiology of a wide
range of liver diseases, such as viral hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Here we
discuss the latest discoveries of FXR functions with relevance to bile acid metabolism and HBV-
associated HCC. More speciﬁcally, the goal of this review is to discuss the roles of FXR and bile acids in
regulating HBV replication and how disregulation of the FXR-bile acid signaling pathway is involved in
HBV-associated hepatocarcinogenesis.
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Farnesoid X receptor (FXR, also termed nuclear receptor
NR1H4) is highly expressed in the liver and intestines and
regulates the expression of a wide variety of genes implicated in
the metabolism of bile acids1–4, glucose4–6, and lipids3–9. Recently,
there is increasing evidence suggesting that activation of FXR
may have beneﬁcial functions in inhibiting liver ﬁbrosis and
cirrhosis9–13, promoting liver cell regeneration14–18, reducing liver
inﬂammatory18–21 and immunological responses18–22, and inhibit-
ing tumorigenesis of the liver23,24, intestine25, prostate26, and
breast27–29.
Despite recent advances in our understanding of the
biological function of FXR in liver diseases, the mechanism
by which FXR inhibits hepatocarcinogenesis remains largely
unknown. Serum and urine metabolomic analyses have sug-
gested several bile acids as potential biomarkers of human
HCC30. Bile acids increased the expression and the replication
of hepatitis B virus (HBV) DNA through promoting the
binding of FXR to FXR response elements (FXREs) located
on the HBV genome31. Most HCC patients have a persistent
sub-clinical and clinical inﬂammatory response, and it is clear
that HBV infection-induced chronic hepatitis and cirrhosis
play a crucial role in hepatocarcinogenesis. Abnormal bile acid
levels owing to the disruption of metabolic homeostasis has
been observed in patients of HBV infection, chronic hepatitis,
cirrhosis and HCC8,13,32,33. Since bile acids are natural ligands
for FXR, it is conceivable that altered bile acid homeostasis
may impact the FXR signaling pathway, which in turn may
affect hepatocarcinogenesis.2. Bile acids as FXR agonists
Bile acids are amphipathic molecules with a steroid backbone,
which are synthesized from cholesterol exclusively in the liver.
Bile acids are physiologically important not only due to their
roles in cholesterol disposal and intestinal lipid absorption,
but also because they can function as signaling molecules34.
The effects of FXR on cell proliferation and apoptosis have
attracted particular attention because of their relevance in
liver diseases and tumorigenesis23–28,31.
FXR plays a critical role in maintaining bile acid home-
ostasis. FXR regulates hepatic bile acid synthesis by inducing
the expression of small heterodimer partner (SHP, or
NR0B2)34 and bile acid transports34–41. Bile acids, as endo-
genous ligands for FXR, bind to and activate FXR, and
subsequently induce the expression of SHP. SHP, in return,
inhibits the expression of the rate-limiting enzyme of bile acid
synthesis, cholesterol 7a hydroxylase (CYP7A1) in the classic
pathway of bile acid biosynthesis42,43. FXR also inhibits the
entry of intestinal bile acids into hepatocytes by repressing
the expression of hepatic bile acid uptake transporters44, the
transport of bile acids by inducing the expression of bile salt
export pump (BSEP), Naþ-taurocholate cotransporting poly-
peptide (NTCP), multidrug resistant-associated protein 2
(MRP2), multidrug resistance protein (MDR)45–47, ﬁbroblast
growth factor 19/15 (FGF19/15)48,49, and bile acid conjuga-
tion to increase the hydrophilicity and detoxiﬁcation of bile
acids50. Overall, activation of FXR plays a protective role in
preventing cholestasis, a condition of liver toxicity due to
excess bile acid accumulation in the liver.3. Bile acids and inﬂammation in liver diseases
When the homeostasis of bile acids is disrupted due to defects
in biosynthesis, hepatic secretion, or enterohepatic cycling, the
accumulated bile acids may result in and aggravate hepatocyte
injury. Under normal physiological conditions, the toxicity of
bile acids is disposed by packaging of bile acids into micelles
and biotransformation of bile acids into non-toxitic metabo-
lites by a series of enzymes in the hepatocytes. However, some
studies have reported that elevated intracellular bile acids,
which is caused by adaptation failures when liver injury
occurs51, can induce inﬂammation of surrounding portal and
periportal liver tissue and activate the Kupffer cells to excrete
cytokines such as TNFa and IL-1b though the JNK/c-Jun
pathway52. Hepatotoxicity induced by high levels of hydro-
phobic bile acids has been observed both in animal models and
human patients. In inﬂammation associated acute phase
response, TNFa and IL-1b inhibit the expression and activity
of CYP7A153. TNFa and CDCA have also been shown to
affect the expression of CYP8B154,55 and CYP27A (sterol 27-
hydroxylase)56. Both IL-1b57,58 and cholic acid (CA) or
deoxycholic acid (DCA)59 were shown to protect hepatocytes
from bile acid toxicity by activating the JNK/c-Jun pathway60.
In prolonged hepatic inﬂammatory conditions, bile acids and
inﬂammatory factors induced intrahepatic cholestasis61,
hypercholesterolemia and dyslipidemia62–64, and liver regen-
eration18–20. Some studies also showed that activation of the
FXR-SHP pathway promoted the resolution of liver ﬁbrosis in
hepatic stellate cells (HSCs)65. It appears that the elevated
serum bile acid levels can be sensitive biomarkers in certain
liver diseases, not only because liver is the central organ in bile
acid metabolism66, but also because changes in bile acid levels
have been proposed as indicators of toxin-induced liver injury
in laboratory animals and HCC30,67,68.4. FXR, bile acids, and replication of hepatitis B virus
HBV is a prototypical member of the hepadnaviruses, which
infects restricted hepatocytes and causes acute and chronic
liver disease. HBV infection is a major risk factor for HCC.
Some studies suggested that bile acids are pro-inﬂammatory
agents. In cholestatic liver disease, chronic exposure to
elevated levels of bile acids might play an important role in
inﬂammation69. Higher levels of cholesterol and bile acids
were observed in FXR null mice. FXR null mice also exhibited
hepatotoxicity after treatment with a high-fat diet. Chen et al.70
found that the elevated serum levels of glycochenodeoxycholic
acid, glycocholic acid, taurocholic acid and chenodeoxycholic
acid were associated with liver cirrhosis and hepatitis68, suggest-
ing that an elevated serum bile acid level can be a sensitive
biomarker for certain liver diseases. However, treatment of
HBV-infected patients with ursodeoxycholic acid showed only
a decline in serum alanine transaminase but no change in HBV
DNA levels7. In 3-month old HBV transgenic mice, there was no
difference in cholestatic and cytolytic indices as well as liver
histology between ursodeoxycholate diet group and the control
mice. However, by 15 months, ursodeoxycholate diet-treated
mice showed a higher hepatocyte proliferation rate compared to
the control group71. A more direct evidence that supports bile
acid’s effect on HBV infection came from the studies showing
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could induce the release of the circular form of HBV-DNA72.
At the mechanistic level, two FXR response elements
located in the HBV Enhancer II and the core promoter
regions have been identiﬁed31. HBV pregenomic RNA synth-
esis and viral replication could be induced by FXR-RXR
heterodimers bound to these two sites as shown by electro-
phoretic mobility shift and luciferase assay73. Another inde-
pendent study also showed that activation of FXR by bile
acids induced HBV gene expression and HBV DNA replica-
tion, attenuated response to interferon-alpha treatment74. SHP
was showed that regulated negatively the nuclear receptor-
dependent hepatitis B virus biosynthesis75.
Taken together, in HBV infection-associated liver diseases,
elevated bile acids can activate FXR and directly enhance HBV
expression and replication through the activation of HBV core
promoter. On the other hand, the FXR target gene SHP plays a
negative role in controlling HBV replication and inhibiting bile
acid metabolism through a negative feedback mechanism.5. HBV infection, FXR, and HCC
It has been established that viral infection is the most important
causal factor of HCC76–78. From the initial HBV infection and
acute hepatitis B to the patients who are already infected and
became chronic hepatitis B and developed into hepatic cirrhosis
and/or long latency of HCC, the exact molecular basis for HBV
to cause HCC remains poorly deﬁned. Two mechanisms have
been proposed for HBV-induced hepatocarcinogenesis: the theory
of chromosomal integration of HBV DNA and the theory of
transcriptional activation mediated by HBx79,80. According to the
‘‘integration theory’’, the integration of HBV DNA can inﬂuence
cellular gene transcription, disturb immune system, cause chronic
inﬂammation, and result in ﬁbrosis, cirrhosis, and HCC.
HBx is the central player in the ‘‘transcriptional activation
theory’’31,81,82. HBx, the smallest of four ORFs of HBV
genome that encodes a 154-amino acid protein, was consid-
ered to be an important etiological factor in HBV-associatedFigure 1 Model of multiple roles of bile acid-FXR signaling pa
accumulation of bile acids, bile acid-FXR signaling pathway is invo
proliferation, and liver regeneration in hepatocarcinogenesis.HCC83–86. HBx can modulate host-cell signal transduction
and directly or indirectly affect host and viral gene expression.
HBx has been shown to transactivate and upregulate proto-
oncogenes Ras, c-Fos and TGF-beta; to silence the tumor
suppressor gene p53, and to affect the NF-kappa B, PKA,
pTEN, and WNT signaling pathways87–100. In HBx-trans-
fected cells, HBx is located not only in the cytoplasm, but also
to some extent, in the nucleus of transfected cells101. Intracel-
lular localization change of HBx is consistent with stimulation
of transcription by activating nuclear receptor signaling path-
ways as a co-factor or co-activator102–112.
It is known that bile acid metabolism is a critical function of
the liver, which is often impaired in chronic hepatitis B and
cirrhosis. Several lines of evidence strongly suggested that
endogenous bile acids are both pro-inﬂammatory and carci-
nogenic113. Long-term exposure to toxic bile acids may trigger
continuous inﬂammation, uncontrolled liver cell proliferation
or irregular liver regeneration68,114–118. Liver regeneration is
an important function to repair injury, and accumulation of
bile acids has been shown to contribute to liver regeneration in
hepatocarcinogenesis20,119,120. For these reasons, changes in
individual serum bile acids levels have been proposed as early
indicators of hepatocarcinogenesis68,119,120.
Normal liver regeneration is dependent on FXR signaling
pathway. Huang et al.18 reported that treatment of wild type
mice with dietary cholic acid accelerated liver regeneration in
the partial hepatectomy model. The effect of cholic acid on
liver regeneration was attenuated in FXR null mice. Inhibition of
NF-kappa B is known to have a protective role in preventing liver
injury and promote liver regeneration. Wang and colleagues
reported that FXR could selectively inhibit the NF-kappa B
mediated hepatic inﬂammatory responses, whereas activation of
NF-kappa B suppressed FXR-mediated gene expression22. FXR
was also found to regulate the activation of liver natural killer
(NK) T cells in acute hepatitis and innate immunity20,121,122.
Consistent with the protective role of FXR, FXR null mice
have been reported to have elevated serum and liver bile acid
levels, serious inﬂammation reactions, ﬁbrosis, apoptosis, and
spontaneous liver tumors23,24. In contrast, activation of FXRthway in HBV infection-associated HCC. In response to the
lved in HBV DNA replication, inﬂammation response, liver cell
Yong-dong Niu et al.76has been found to alleviate age-related proliferation in
regenerating mouse livers by interacting with the transcription
factor forkhead box m1b16. The interaction between FXR and
PPAR was found to play a role in the anti-ﬁbrotic activity of
FXR in a rodent model of liver cirrhosis11.
SHP, as a primary FXR target gene, also plays a role in
HCC. Huang and colleagues observed spontaneous liver
tumors from adenocarcinomas to carcinomas with massive
hepatocyte proliferation in 55% of 15-month old SHP null
mice, suggesting that SHP is an anti-oncoprotein. SHP may
suppress tumorigenesis by modulating cyclin D1 expression
and targeting the mitochondria123,124.6. Summary and perspectives
Epidemiological studies have suggested that exposure to
xenobiotics and/or endogenous toxic metabolites and viral
infection are major risk factors for HCC. Bile acids represent
an early indicator of hepatocarcinogenesis. Activation of FXR
not only prevents hepatocarcinogenesis by regulating the NF-
kappa B signaling pathway to inhibit the injury caused by the
persistent immune response and cytotoxicity induced by the
virus products and accumulation of toxic bile acids, but also
affects HBV DNA replication. Fig. 1 summarizes the major effect
of FXR and bile acid on HBV-associated HCC, although many
detailed mechanisms for the FXR and bile acid effect remain to be
deﬁned. It is also recognized that there is insufﬁcient evidence to
support or refute the long-term effect of bile acids in HCC.
Further understanding the role of FXR and bile acids in HCC
may eventually help to develop novel therapies for the prevention
and treatment of HCC.
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